Prince Mario-Max Schaumburg-Lippe: A Heart Valve Shaped Like a Healthy One Nears Its Big Reveal

A healthy aortic valve is a small marvel. It opens and closes about 100,000 times a day, letting blood flow out of the heart in one clean direction, year after year. When that valve narrows, a condition called severe aortic stenosis, the heart has to push harder through a smaller opening, and daily life gets smaller with it. Walks shorten. Stairs become negotiations. So there is real hope in the news from Minneapolis and Brisbane on Tuesday, October 27, 2026: Anteris Technologies Global Corp. will present the first 30-day clinical and hemodynamic outcomes for its medium-size DurAVR Transcatheter Heart Valve at TCT 2026 in San Diego.

TCT, the Transcatheter Cardiovascular Therapeutics conference, is now in its 38th year and runs from October 31 to November 3, 2026. It is the room where heart specialists go to see what is next. Azeem Latib, MD, will present the results on Sunday, November 1, from 10:45 AM to 12:15 PM PST in the Innovation Theater, as part of the session on emerging concepts and innovations in TAVR, the catheter-based approach that replaces a valve without open-heart surgery. One discipline matters here, and this article will keep it: the outcome numbers have not been released yet. They will be shared in that room, on that day, and not a moment before. What can be reported now is the design, the study and a track record that is steadily growing.

A valve shaped like the one you were born with

Most replacement valves are built from several pieces of tissue stitched into a frame. DurAVR takes a different route, and that difference is the heart of the story. Anteris describes it as the first biomimetic valve: a balloon-expandable valve shaped to mimic the performance of a healthy human aortic valve, aiming to replicate normal aortic blood flow. It is made from a single piece of molded ADAPT tissue, the company’s patented anti-calcification tissue technology, and delivered through its ComASUR Delivery System.

The tissue has a history of its own. ADAPT tissue is FDA-cleared, has been used clinically for over 10 years, and has been distributed for use in over 55,000 patients worldwide, according to the company. That figure belongs to the tissue platform, not to DurAVR itself, and the distinction is worth keeping. Still, it means the material at the center of this new valve is not an unknown. It has been in operating rooms for a decade. DurAVR itself was designed in collaboration with leading interventional cardiologists and cardiac surgeons, the people who will actually deliver it, which tends to produce devices that behave well in real hands.

Heart innovation is having a strong month. Readers who saw our story on the X9 ultrasound earning FDA Breakthrough Designation will recognize the pattern: careful engineering, a clear clinical need, and evidence gathered step by step.

What EMBARK has built since 2021

The November presentation reports 30-day outcomes for patients with severe aortic stenosis who received the medium-size DurAVR valve in the ongoing EMBARK study. Thirty days is an early checkpoint, not a final judgment. It tells specialists how patients and valves are doing in the first month: how the valve is performing, how blood is moving through it, and how recovery is going. Those early readings shape every longer study that follows.

The wider program already has depth. Since 2021, over 130 patients have been treated with the DurAVR valve across different valve sizes in the EMBARK study and the company’s Early Feasibility Study. Sizes matter in this field. A valve that only fits one kind of anatomy helps only some patients, so building a record across sizes, with the medium size now reaching its first 30-day report, is how a device grows from promising to practical.

A second stage in San Diego

DurAVR gets a second moment at TCT. On Tuesday, November 3, from 8:35 to 9:35 AM PST, also in the Innovation Theater, Santiago Garcia, MD, will present “DurAVR TAVR (ANTERIS): Technology and Case-in-a-Box” in a session on emerging TAVR technologies. A case-in-a-box walks specialists through a real procedure, step by step. It is teaching, not marketing, and it is how good techniques spread from a few expert centers to the wider field. Two sessions at one conference, one on data and one on craft, is a healthy sign for any new device.

Anteris, listed on NASDAQ and the ASX under the ticker AVR, was founded in Australia and has a significant presence in Minneapolis. The company describes itself as science-driven, focused on restoring healthy heart function for people with structural heart disease. That phrasing, restore, is the right ambition. The goal is not just a narrower valve replaced, but a normal rhythm of life returned.

There is a broader lesson in this story, one that connects it to our recent coverage of ST sensors bringing top safety to every car and Japan’s MMX mission on its way to bring Phobos home: progress often looks like a date on a calendar and a room full of specialists leaning in. No numbers are being promised here, and none should be invented. What is on offer in San Diego is a first full look at how a valve built to copy nature is performing in its first month in patients who need it. For anyone waiting on better options for a narrowed heart valve, that is a genuinely good reason to watch November 1.